NCT04690920

Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: University of Lahore · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose

Conditions

• Corona Virus Disease 2019 (COVID-19)

Interventions

Type	Name	Description
DRUG	Tocilizumab	Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Timeline

• Start date: 2020-07-23
• Primary completion: 2020-12-10
• Completion: 2020-12-10
• First posted: 2020-12-31
• Last updated: 2020-12-31

Locations

1 site across 1 country: Pakistan